ArticleAmerican journal of respiratory and critical care medicine2024
Commensal Oral Microbiota, Disease Severity, and Mortality in Fibrotic Lung Disease.
Open access · greenAbstract readMulticenter Study
In one paragraph
Article in American journal of respiratory and critical care medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
5.7field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 22 citations in OpenAlex.
- The role of the respiratory microbiome in acute and chronic respiratory diseases.Nature reviews. Microbiology · 2026Review
- Gut microbiota associate with disease severity and survival in idiopathic pulmonary fibrosis.American journal of respiratory and critical care medicine · 2026Article
- Inter-Organ Communication in Pulmonary Fibrosis: Systemic Modifiers of a Lung-Centered Disease.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Review
- Oral microbiome dysbiosis and oral-gut microbial network disruption in hand osteoarthritis: data from the Xiangya Osteoarthritis Study.RMD open · 2026Observational
- Role of oral bacteria composition and functional gene profiles in respiratory diseases.BMJ open respiratory research · 2026Article
- From lab to law: emerging applications, potential benefits, evolving regulatory framework and challenges for engineered probiotics.Microbial cell factories · 2026Review
- Prediction of baseline oral microbiota for clinical classification post Omicron variant of SARS-CoV-2 infection.Scientific reports · 2026Article
- Targeted lungScience advances · 2026Article
- Smoking-induced microbial dysbiosis: a key driver of systemic diseases and emerging therapeutic opportunities.Cell death discovery · 2025Review
- Oral microbiota: Roles and treatment in radiation injury (Review).Oncology letters · 2025Review
- Bacterial Pneumonia Alters the Respiratory Microbiota and Inflammatory Profile Via the Lung Microbiome-Immune Axis.Current microbiology · 2025Article
- Proteomic Biomarkers of Survival in Non-Idiopathic Pulmonary Fibrosis Interstitial Lung Disease.American journal of respiratory and critical care medicine · 2025Article
- Oral microbiota and respiratory diseases: advances and perspectives.Clinical microbiology reviews · 2025Review
- The Respiratory Tract Microbiome and Human Health.Microbial biotechnology · 2025Review
- Clinical translation of microbiome research.Nature medicine · 2025Review
- The lung microbiome in interstitial lung disease.Breathe (Sheffield, England) · 2025Review
- Assessment of upper respiratory and gut bacterial microbiomes during COVID-19 infection in adults: potential aerodigestive transmission.Scientific reports · 2025Article
- Periodontitis aggravates pulmonary fibrosis byFrontiers in cellular and infection microbiology · 2025Article
- Reply to WardAmerican journal of respiratory and critical care medicine · 2024Article
- Integrating Aerodigestive Investigations in Progressive Pulmonary Fibrosis.American journal of respiratory and critical care medicine · 2024Article
Corrections and comments
- Commented on by
Authors and funding
15 authors at 7 institutions in 1 country.
David N O'DwyerDepartment of Medicine, University of Michigan Medical School, Ann Arbor, Michigan.ORCID 0000-0003-3214-380X
John S KimDepartment of Medicine, University of Virginia School of Medicine, Charlottesville, Virginia.
Shwu-Fan MaDepartment of Medicine, University of Virginia School of Medicine, Charlottesville, Virginia.
Piyush RanjanDepartment of Medicine, University of Michigan Medical School, Ann Arbor, Michigan.
Promi DasDepartment of Pediatrics, University of California San Diego, San Diego, California.
Jay H LipinskiDepartment of Medicine, University of Michigan Medical School, Ann Arbor, Michigan.
Joseph D MetcalfDepartment of Medicine, University of Michigan Medical School, Ann Arbor, Michigan.
Nicole R FalkowskiDepartment of Medicine, University of Michigan Medical School, Ann Arbor, Michigan.
Eric YowDepartment of Biostatistics, Duke University, Durham, North Carolina.
Kevin AnstromDepartment of Biostatistics, University of North Carolina-Chapel Hill Gillings School of Global Public Health, Chapel Hill, North Carolina.
Robert P DicksonDepartment of Medicine, University of Michigan Medical School, Ann Arbor, Michigan.ORCID 0000-0002-6875-4277
Yong HuangDepartment of Medicine, University of Virginia School of Medicine, Charlottesville, Virginia.
Jack A GilbertDepartment of Pediatrics, University of California San Diego, San Diego, California.
Fernando J MartinezDepartment of Medicine, Weill Cornell Medical Center, New York, New York.
Imre NothDepartment of Medicine, University of Virginia School of Medicine, Charlottesville, Virginia.
University of Michigan · USUniversity of Virginia · USUniversity of California San Diego · USCornell University · USDuke University · USUnited States University · USUniversity of North Carolina at Chapel Hill · US
Funding
1/2 Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases studyUH3HL145266 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI MARTINEZ, FERNANDO J, NOTH, IMRE · 2021 to 2025
$11.6MArchitectural structure and regulation of TOLLIP in IPFR01HL130796 · NHLBI · UNIVERSITY OF VIRGINIA · PI NOTH, IMRE · 2016 to 2019
$3.1MGut Microbiota and Host Regulatory Cross-Talk in Pulmonary FibrosisR01HL162659 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI O'DWYER, DAVID NOEL · 2022 to 2025
$1.9MStudy of Co-trimoxazole and Proton Pump Inhibition Using Pragmatic Design in Idiopathic Pulmonary Fibrosis - CleanUP-IPFU01HL128964 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI ANSTROM, KEVIN J, MARTINEZ, FERNANDO J · 2015 to 2018
$1.6MRole of polyunsaturated fatty acids in pulmonary fibrosisK23HL150301 · NHLBI · UNIVERSITY OF VIRGINIA · PI KIM, JOHN S · 2021 to 2025
$858kIllumina NovaSeq 6000 Sequencing SystemS10OD026929 · OD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI JEPSEN, KRISTEN LYNN · 2019 to 2019
$600kNHLBI NIH HHS K23 HL150301NHLBI NIH HHS K23HL150301NHLBI NIH HHS R01 HL130796NHLBI NIH HHS R01 HL162659NHLBI NIH HHS U01 HL128964NHLBI NIH HHS UH3 HL145266NIH HHS S10 OD026929
Abstract
PubMed holds no abstract for this paper.
Indexed as
Idiopathic Pulmonary FibrosisMicrobiotaSeverity of Illness IndexAgedFemaleHumansMaleMiddle AgedMouthProportional Hazards ModelsRNA, Ribosomal, 16SRNA, Ribosomal, 16Sbuccal microbiomedisease progressionidiopathic pulmonary fibrosis
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.